Last week, the FDA announced that it had officially approved Spravato, a brand-name nasal spray containing esketamine, a chemical cousin of ketamine, to treat depression.The drug was hailed by ...

Nasal esketamine spray is more effective than an extended-release antipsychotic, when both are taken in combination with SSRIs and SNRIs, in treatment-resistant depression, a study found.

Spravato, a nasal spray esketamine, was found to work better than Seroquel for treatment-resistant depression, a study in the New England Journal of Medicine finds.

This week, the FDA approved esketamine, the first nasal spray to treat depression in adults who have tried other antidepressant medications without success. Esketamine, which the FDA approved to ...

Source Reference: Daly E, et al "Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression" JAMA Psychiatry 2019 ...

Interest in the use of ketamine for the treatment of depression has risen in recent years. Two clinicians discussed the lessons they have learned in using ketamine and esketamine as adjunctive ...

Esketamine is for patients with "treatment-resistant depression," a major depressive disorder that at least two alternative antidepressant treatments failed to adequately address.

Ketamine Esketamine for Depression: New FDA Approval, New Controversy A new medication may have good potential but serious risks. Posted July 3, 2019 ...

Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States. Psychiatric Services , 2020; appi.ps.2019006 DOI: 10.1176/appi.ps.201900625 Cite ...

Esketamine — developed by Johnson & Johnson and delivered as a nasal spray — would be used in combination with oral antidepressants in patients with depression that haven’t responded to ...

In one monthlong study, those on esketamine performed better statistically than those on placebo, reducing scores on a standard, 60-point depression scale by 21 points, compared to 17 points for ...

Esketamine, the nasal-spray antidepressant recently approved by the F.D.A., is promising, but using it entails some practical challenges. By Benedict Carey Doctors welcomed federal approval this ...